EM Imaging is Drug Discovery in United Kingdom that focus on compounds development business. Founded in 2014. They cover business area such as developer, optical tracer, therapeutic compound development, small molecule, peptide, radionuclide, fluorescent dye, specifically cancerous cell, healthcare professional, disease, real-time, interventional procedure, surgery, accurate treatment, healthy tissue.
2014
( 10 years old in 2024 )
Compounds Development
-
9 Little France Road
Edinburgh BioQuarter (Gate 3)
Edinburgh EH16 4UX
Scotland, United Kingdom
Private
developeroptical tracertherapeutic compound developmentsmall moleculepeptideradionuclidefluorescent dyespecifically cancerous cellhealthcare professionaldiseasereal-timeinterventional proceduresurgeryaccurate treatmenthealthy tissue
* We use standard office opening hours in near EM Imaging's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
EM Imaging is Drug Discovery business from United Kingdom that founded in 2014 (10 years old in 2024), EM Imaging business is focusing on Compounds Development.
EM Imaging headquarter office and corporate office address is located in 9 Little France Road Edinburgh BioQuarter (Gate 3) Edinburgh EH16 4UX Scotland, United Kingdom.
EM Imaging was founded in United Kingdom.
In 2024, EM Imaging is currently focus on compounds development sector.
Above is snippet of Google Trends for "compounds development" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with EM Imaging, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.